Silvia Heltai

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4235650/publications.pdf

Version: 2024-02-01

33	1,664	471061 17	476904 29
papers	citations	h-index	g-index

33	33	33	1930
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer. , 2019, 7, 45.		54
2	Relevance of Minimal Residual Disease in the Era of Targeted Agents. Cancer Journal (Sudbury, Mass), 2019, 25, 410-417.	1.0	8
3	Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment. Haematologica, 2018, 103, 707-716.	1.7	36
4	Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma. Frontiers in Immunology, 2018, 9, 3171.	2.2	9
5	Basophil Recruitment into Tumor-Draining Lymph Nodes Correlates with Th2 Inflammation and Reduced Survival in Pancreatic Cancer Patients. Cancer Research, 2016, 76, 1792-1803.	0.4	114
6	Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival. OncoImmunology, 2015, 4, e1005460.	2.1	37
7	Abstract 443: Mechanisms of IL-1 production and release in pancreatic cancer cells. , 2015, , .		0
8	Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms. Journal of Translational Medicine, 2014, 12, 335.	1.8	13
9	A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses. Journal of Immunological Methods, 2012, 375, 46-56.	0.6	11
10	Nef-specific CD45RA+ CD8+ T cells secreting MIP-1Î² but not IFN-Î³ are associated with nonprogressive HIV-1 infection. AIDS Research and Therapy, 2010, 7, 20.	0.7	8
11	The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT. AIDS Research and Therapy, 2008, 5, 22.	0.7	19
12	Nef Alleles from Human Immunodeficiency Virus Type 1-InfectedLong-Term-Nonprogressor Hemophiliacs with or without Late Disease Progression Are Defective in Enhancing Virus Replication and CD4 Down-Regulation. Journal of Virology, 2006, 80, 10663-10674.	1.5	39
13	Evidence for the Involvement of Phosphatidylinositol 3-Kinase in fMLP-Stimulated Neutrophil Adhesion to ICAM-1-Transfected Cells. Journal of Cardiovascular Pharmacology, 2001, 37, 751-761.	0.8	12
14	In vivo administration of GM-CSF promotes the clearance of apoptotic cells: effects on monocytes and polymorphonuclear leukocytes. Journal of Leukocyte Biology, 2000, 67, 174-182.	1.5	25
15	Engagement of CD30 shapes the secretion of cytokines by human Î³ Î´ T cells. European Journal of Immunology, 2000, 30, 2172-2180.	1.6	22
16	Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes. , 1999, 81, 573-579.		19
17	Apoptotic cell clearance in systemic lupus erythematosus: I. Opsonization by antiphospholipid antibodies. Arthritis and Rheumatism, 1998, 41, 205-214.	6.7	202
18	Apoptotic cell clearance in systemic lupus erythematosus: II. Role of ?2-glycoprotein I. Arthritis and Rheumatism, 1998, 41, 215-223.	6.7	143

#	Article	IF	Citations
19	Mycobacterium tuberculosisexploits the CD95/CD95 ligand system of Î³â€‰Î´ T cells to cause apoptosis. European Journal of Immunology, 1998, 28, 1798-1806.	1.6	46
20	Human Melanoma Cells Transfected with the B7-2 Co-Stimulatory Molecule Induce Tumor-Specific CD8⁺Cytotoxic T LymphocytesIn Vitro. Human Gene Therapy, 1998, 9, 1335-1344.	1.4	25
21	Autocrine Nitric Oxide Modulates CD95-induced Apoptosis in Î³Î´ T Lymphocytes. Journal of Biological Chemistry, 1997, 272, 23211-23215.	1.6	102
22	Quantitative cytometry of MHC class I digestion from living cells. , 1997, 27, 77-83.		9
23	Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. European Journal of Immunology, 1996, 26, 1851-1859.	1.6	52
24	Fas, apoptosis and the cell cycle. Trends in Immunology, 1996, 17, 345-346.	7.5	3
25	Killing of Laminin Receptor-Positive Human Lung Cancers by Tumor-Infiltrating Lymphocytes Bearing Î³Î´ + T-Cell Receptors. Journal of the National Cancer Institute, 1996, 88, 436-441.	3.0	60
26	Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. European Journal of Immunology, 1995, 25, 1154-1162.	1.6	111
27	Constitutive expression of the heat shock protein 72 kDa in human melanoma cells. Cancer Letters, 1994, 85, 211-216.	3.2	29
28	Role of interleukin-2 in regulating lymphocyte activation and recirculation. European Journal of Cancer, 1993, 29, 474-475.	1.3	4
29	Unusual expression and localization of heat-shock proteins in human tumor cells. International Journal of Cancer, 1992, 51, 613-619.	2.3	417
30	Autoimmune Thyroiditis following Interleukin-2 and Lak Cell Therapy for Metastatic Renal Cell Carcinoma: Correlation with Tumor Regression. Tumori, 1991, 77, 339-342.	0.6	6
31	Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: II. characterization of cells cultured ex vivo and their contribution to the in vivo immunomodulation. Cancer Immunology, Immunotherapy, 1991, 33, 128-132.	2.0	10
32	Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. phenotypic and functional analysis of the peripheral blood mononuclear cells. Cancer Immunology, Immunotherapy, 1990, 32, 161-166.	2.0	16
33	Dual-parameter flow cytometric analysis of an early lymphocyte activation antigen (CK226) and DNA content. Cytometry, 1989, 10, 762-771.	1.8	3